<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13740">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928042</url>
  </required_header>
  <id_info>
    <org_study_id>PVAP69</org_study_id>
    <nct_id>NCT02928042</nct_id>
  </id_info>
  <brief_title>Inhibition Effects of Probiotics on Pathogens Associated With VAP</brief_title>
  <official_title>Inhibition Effects of Probiotics on Pathogens Associated With Ventilator Associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dilek Özcengiz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cukurova University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates that P. aeruginosa, A. baumannii, Staphy. aureus and K. pneumonia which
      are obtained from patients' tracheal aspiration culture who treated with mechanical
      ventilation will be compared with Lactobacillus (LAB) members in the laboratory. The aim is
      to investigate the probiotics' antimicrobial properties and effects on these bacteria's
      growth rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ventilator associated pneumonia (VAP) is one of the most commonly seen hospital-acquired
      infections that occurs in patients who receive mechanical ventilation. VAP usually occurs
      48-72 hours after mechanical ventilation and is related increased incidence of
      multidrug-resistant infections, increased antibiotic use, extended mechanical ventilation
      time, increased patient stay in the intensive care unit (ICU), and increased patient stay in
      the hospital. One recent intervention is the probiotic therapy which is a nonantibiotic
      strategy for maintenance of the host's aerodigestive microbial balance and VAP
      prevention.Common causative pathogens of VAP include Gram negative bacteria such as
      Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter species, and Gram-positive
      bacteria such as Staphylococcus aureus. In this study, these pathogens obtained from
      mechanical ventilated patients' tracheal aspiration culture and reference bacteria strains
      will be compared with Lactobacillus (LAB) members in the laboratory. Probiotics'
      antimicrobial properties and effects on these bacteria's (obtained from patients and
      reference strains) growth rate will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Months</target_duration>
  <primary_outcome>
    <measure>Probiotics' antimicrobial properties and effects on P. aeruginosa, A. baumanii, Staph. auresu and K. pneumonia's growth rate.</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Lactobacillus bacteria</arm_group_label>
    <description>Pseudomonas aeruginosa, Acinetobacter baumanii, Staphylococcus aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 60 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) will be investigated on the bacteria's growth rate in the laboratory.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference bacteria</arm_group_label>
    <description>Pseudomonas aeruginosa, Acinetobacter baumanii, Staphylococcus aureus and Klebsiella pneumonia reference strains will be used for positive control trial. Antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) will be investigated on the bacteria's growth rate in the laboratory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactobacillus bacteria</intervention_name>
    <description>Antimicrobial effects of Lactobacillus bacteria (LAB) on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.</description>
    <arm_group_label>Lactobacillus bacteria</arm_group_label>
    <arm_group_label>Reference bacteria</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who mechanically ventilated at least 48 hours will be included. Patients'
        tracheal aspirate cultures will be used for study. Pseudomonas aeruginosa, Acinetobacter
        baumanii, Staphylococcus aureus and Klebsiella pneumoniae will be isolated from tracheal
        aspiration cultures.Antimicrobial effects of Lactobacillus members will be investigated on
        the bacteria's growth rate in the laboratory.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who mechanically ventilated at least 48 hours in the intensive care unit

        Exclusion Criteria:

          -  Patients who mechanically ventilated less than 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilek Özcengiz, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cukurova University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feride Karacaer, Specialist</last_name>
    <phone>+90322 3386060</phone>
    <phone_ext>3264</phone_ext>
    <email>feridekaracaer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dilek Özcengiz, Professor</last_name>
    <phone>+90322 3386060</phone>
    <phone_ext>3289</phone_ext>
    <email>dilekozcengiz@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feride Karacaer, Specialist</last_name>
      <phone>+90322 3386060</phone>
      <phone_ext>3264</phone_ext>
      <email>feridekaracaer@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dilek Özcengiz, Professor</last_name>
      <phone>+90322 3386060</phone>
      <phone_ext>3289</phone_ext>
      <email>dilekozcengiz@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Alexandre Y, Le Berre R, Barbier G, Le Blay G. Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections. BMC Microbiol. 2014 Apr 27;14:107. doi: 10.1186/1471-2180-14-107.</citation>
    <PMID>24766663</PMID>
  </reference>
  <reference>
    <citation>Petrof EO, Dhaliwal R, Manzanares W, Johnstone J, Cook D, Heyland DK. Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit Care Med. 2012 Dec;40(12):3290-302. doi: 10.1097/CCM.0b013e318260cc33. Review.</citation>
    <PMID>22975886</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 31, 2016</lastchanged_date>
  <firstreceived_date>October 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cukurova University</investigator_affiliation>
    <investigator_full_name>Feride Karacaer</investigator_full_name>
    <investigator_title>Specialist doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
